Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Shares Outstanding (Weighted Average) (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 215.53% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.5 million, a 215.53% increase, with the full-year FY2025 number at $1.6 million, changed N/A from a year prior.
  • Shares Outstanding (Weighted Average) was $4.5 million for Q4 2025 at Neuphoria Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $981.6 million in Q2 2023 to a low of $1.3 million in Q3 2024.
  • A 3-year average of $142.1 million and a median of $1.7 million in 2025 define the central range for Shares Outstanding (Weighted Average).
  • Biggest YoY gain for Shares Outstanding (Weighted Average) was 215.53% in 2025; the steepest drop was 72.77% in 2025.
  • Neuphoria Therapeutics' Shares Outstanding (Weighted Average) stood at $981.6 million in 2023, then plummeted by 99.85% to $1.4 million in 2024, then soared by 215.53% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Shares Outstanding (Weighted Average) are $4.5 million (Q4 2025), $2.2 million (Q3 2025), and $1.6 million (Q2 2025).